期刊文献+

紫杉醇冻干纳米乳在大鼠体内的药动学 被引量:6

The Pharmacokinetics of Lyophilized Paclitaxel Nanoemulsions in Rats
下载PDF
导出
摘要 目的: 研究紫杉醇冻干纳米乳在大鼠体内的药动学特征.方法: 建立测定大鼠血浆中紫杉醇的HPLC-紫外检测法,大鼠股静脉注射给药后于不同时间点进行后眼眶静脉丛穿刺取血,测定其血浆中的血药浓度,并用3P97药动学程序对血药浓度进行处理.结果: 紫杉醇可与血浆中的其它成分较好地分离,在0.12~60 μg/mL的血药浓度范围内呈良好的线性关系.紫杉醇注射液和冻干纳米乳两种制剂大鼠静脉给药后体内药动学符合二室模型,后者AUC和MRT均大于前者.结论: 紫杉醇纳米乳可延长药物在大鼠体内的循环时间. AIM: Study the pharmacokinetic characteristics of paelitaxel lyophilized nanoemulsions in rats. METHOD: A reversed-phase HPLC with UV detection was developed and validated for simultaneous analysis of paclitaxel in rat plasma. The plasma concentrations of paclitaxel were detected at various times following a femoral intravenous administration of paclitaxel at a close of 10 mg/kg body weight. The data was processed with the pharmacokinetic software 3P97. RESULT: A good separation of paclitaxel with other substances in plasma was obtained. The assay was liner over the range 0.12 ~ 60 μg/mL. The paclitaxel concentration-time curve profiles after iv. Both paclitaxel injections and nanoemulsions conformed to a two-compartment model. But the AUC and MRT of latter are bigger than the former. CONCLUSION: The nanoemulsions can prolong the circulating time of paclitaxel.
出处 《中国天然药物》 SCIE CAS CSCD 2005年第6期370-372,共3页
关键词 紫杉醇 纳米乳 冻干 药动学 Paclitaxel Lyophilized Nanoemulsions Pharmacokinetics
  • 相关文献

参考文献3

二级参考文献24

  • 1王鸿,杨纲,梁文权.盐酸布比卡因冻干乳剂的制备[J].海峡药学,2004,16(4):21-22. 被引量:7
  • 2[1]Tarr B D, Sambandau T G, Yalkowsky S H. A new parenteral emulsi on for the administration of taxol[J]. Pharm Res, 1987, 4: 162-165.
  • 3[2]Shama A, Mayhew E, Straubinger R M. Antitumor effect of taxol-contai ning liposomes in a taxol-resistant murine tumor model [J]. Cancer Res,19 93, 53: 5877-5881.
  • 4[3]Balasubramanian S V, Straubinger R M. Taxol-lipid interactions: taxo l dependent effects on the physical properties of model membranes [J]. Bioch emistry, 1994, 33: 8941-8947.
  • 5[4]Sharma A, Sharma U S, Straubinger R M. Paclitaxel-liposomes for intr acavitary therapy of intraperitoneal P388 leukemia [J]. Cancer Lett, 1996, 107: 265-272.
  • 6[5]Sharma U S, Balasubramanian S V, Straubinger R M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins [J]. J Pharm Sci, 1995, 84: 1223-1230.
  • 7[6]Sharma A, Straubinger R M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes [J]. Pharm Res, 1994,11: 8 89-898.
  • 8[7]Pendri A, Conover C D, Greenwald R B. Antitumor activity of paclitaxe l-2-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug [ J]. Anticancer Drug Des, 1998, 13: 387-395.
  • 9[8]Ke S, Milas L, Charnsangavej C. Potentiation of radioresponse by poly mer-drug conjugates [J]. J Control Rel, 2001, 74: 237-242.
  • 10[9]Dordunoo S K, Jackson J K, Arsenault L A, et al. Taxol encapsulation in poly(ε-caprolactone) microspheres [J]. Cancer Chemother Pharmacol, 19 95, 36: 279-282.

共引文献36

同被引文献61

引证文献6

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部